Compare QUBT & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | CLDX |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2019 | 1995 |
| Metric | QUBT | CLDX |
|---|---|---|
| Price | $7.39 | $32.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $17.00 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 9.3M | 933.0K |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $682,000.00 | ★ $12,743,000.00 |
| Revenue This Year | $413.34 | $111.39 |
| Revenue Next Year | $479.21 | $235.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 82.84 | ★ 87.78 |
| 52 Week Low | $5.76 | $14.40 |
| 52 Week High | $25.84 | $31.85 |
| Indicator | QUBT | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 64.64 |
| Support Level | N/A | $24.70 |
| Resistance Level | $9.15 | N/A |
| Average True Range (ATR) | 0.42 | 1.49 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 36.07 | 61.52 |
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.